Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Starpharma Holdings Limited - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Starpharma Holdings Limited - Product Pipeline Review - 2015', provides an overview of the Starpharma Holdings Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Starpharma Holdings Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Starpharma Holdings Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Starpharma Holdings Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Starpharma Holdings Limited's pipeline products Reasons to Buy - Evaluate Starpharma Holdings Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Starpharma Holdings Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Starpharma Holdings Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Starpharma Holdings Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Starpharma Holdings Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Starpharma Holdings Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Starpharma Holdings Limited Snapshot 5 Starpharma Holdings Limited Overview 5 Key Information 5 Key Facts 5 Starpharma Holdings Limited - Research and Development Overview 6 Key Therapeutic Areas 6 Starpharma Holdings Limited - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Starpharma Holdings Limited - Pipeline Products Glance 12 Starpharma Holdings Limited - Late Stage Pipeline Products 12 Phase III Products/Combination Treatment Modalities 12 Starpharma Holdings Limited - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Starpharma Holdings Limited - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Starpharma Holdings Limited - Drug Profiles 16 astodrimer 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 docetaxel 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 doxorubicin dendrimer 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 insulin human dendrimer 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Monoclonal Antibody Conjugate to Target Her2 for Ovarian Cancer 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 oxaliplatin dendrimer 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Starpharma Holdings Limited - Pipeline Analysis 23 Starpharma Holdings Limited - Pipeline Products by Target 23 Starpharma Holdings Limited - Pipeline Products by Route of Administration 24 Starpharma Holdings Limited - Pipeline Products by Molecule Type 25 Starpharma Holdings Limited - Pipeline Products by Mechanism of Action 26 Starpharma Holdings Limited - Recent Pipeline Updates 27 Starpharma Holdings Limited - Company Statement 31 Starpharma Holdings Limited - Locations And Subsidiaries 33 Head Office 33 Other Locations & Subsidiaries 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35
List of Tables
Starpharma Holdings Limited, Key Information 5 Starpharma Holdings Limited, Key Facts 5 Starpharma Holdings Limited - Pipeline by Indication, 2015 7 Starpharma Holdings Limited - Pipeline by Stage of Development, 2015 8 Starpharma Holdings Limited - Monotherapy Products in Pipeline, 2015 9 Starpharma Holdings Limited - Partnered Products in Pipeline, 2015 10 Starpharma Holdings Limited - Partnered Products/ Combination Treatment Modalities, 2015 11 Starpharma Holdings Limited - Phase III, 2015 12 Starpharma Holdings Limited - Phase II, 2015 13 Starpharma Holdings Limited - Phase I, 2015 14 Starpharma Holdings Limited - Preclinical, 2015 15 Starpharma Holdings Limited - Pipeline by Target, 2015 23 Starpharma Holdings Limited - Pipeline by Route of Administration, 2015 24 Starpharma Holdings Limited - Pipeline by Molecule Type, 2015 25 Starpharma Holdings Limited - Pipeline Products by Mechanism of Action, 2015 26 Starpharma Holdings Limited - Recent Pipeline Updates, 2015 27 Starpharma Holdings Limited, Subsidiaries 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.